Literature DB >> 6396765

Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.

H T Mouridsen, C Rose, H Brincker, S M Thorpe, F Rank, K Fischerman, K W Andersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6396765     DOI： 10.1007/978-3-642-82357-2_14

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  4 in total

1.  Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status.

Authors:  C Rose; H T Mouridsen; S M Thorpe; J Andersen; M Blichert-Toft; K W Andersen
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

2.  Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.

Authors:  T Saarto; C Blomqvist; P Rissanen; A Auvinen; I Elomaa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.

Authors:  P Poikonen; T Saarto; J Lundin; H Joensuu; C Blomqvist
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

Review 4.  Tamoxifen and oxidative stress: an overlooked connection.

Authors:  Nermin S Ahmed; Marek Samec; Alena Liskova; Peter Kubatka; Luciano Saso
Journal:  Discov Oncol       Date:  2021-05-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.